Skip to main content

Table 3 Risk factors for disease-free survival in stage IB NSCLC

From: Efficacy of platinum-based adjuvant chemotherapy in T2aN0 stage IB non-small cell lung cancer

 

Univariate analysis

Multivariate analysis (Cox hazard model)

 

HR (95% CI)

p value

HR (95% CI)

p value

Age

1.032 (1.004-1.062)

0.028

1.022 (0.994-1.051)

0.132

Sex (female vs. male)

0.795 (0.427-1.480)

0.470

ECOG   1 (vs. 0)

1.679 (0.895-3.149)

0.107

1.552 (0.802-3.002)

0.192

      2 (vs. 0)

0.802 (0.107-5.989)

0.829

0.980 (0.113-8.464)

0.985

Pneumonectomy

1.176 (0.421-3.290)

0.757

Tumor size

0.998 (0.970-1.027)

0.897

Numbers of dissected lymph nodes

0.984 (0.960-1.010)

0.207

Adenocarcinoma (vs. non-adenocarcinoma)

1.220 (0.675-2.206)

0.509

Differentiation (moderate to poor vs. well)

1.675 (0.874-3.211)

0.120

Lymphovascular invasion

0.827 (0.322-2.124)

0.692

Pleural invasion (pl2 and pl1 vs. pl0)

0.953 (0.458-1.983)

0.897

Platinum based chemotherapy (vs. no adjuvant therapy)

0.454 (0.244-0.847)

0.013

0.507 (0.263-0.978)

0.043